×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Americas Gastrointestinal Drugs Market

ID: MRFR/Pharma/0140-HCR
50 Pages
Kinjoll Dey
October 2025

Americas Gastrointestinal Drugs Market Research Report, by Drug Category (Acid Neutralizers, Laxatives and Antidiarrheal, Anti-inflammatory drugs, and Others), By Route of Administration (Oral, Parenteral, Rectal), By disease type (Gastroesophageal Reflux Disease, Inflammatory Bowel Disease and Other), By end user (Hospital Pharmacies, Retail Pharmacies and Other) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Americas Gastrointestinal Drugs Market Infographic
Purchase Options

Americas Gastrointestinal Drugs Market Summary

The United States of America gastrointestinal drugs market is projected to grow from 12.3 USD billion in 2024 to 19.7 USD billion by 2035.

Key Market Trends & Highlights

Americas Gastrointestinal Drugs Market Key Trends and Highlights

  • The market is expected to experience a compound annual growth rate of 4.34 percent from 2025 to 2035.
  • By 2035, the gastrointestinal drugs market in the United States is anticipated to reach a valuation of 19.7 USD billion.
  • In 2024, the market is valued at 12.3 USD billion, indicating a robust growth trajectory.
  • Growing adoption of innovative treatment options due to increasing prevalence of gastrointestinal disorders is a major market driver.

Market Size & Forecast

2024 Market Size 12.3 (USD Billion)
2035 Market Size 19.7 (USD Billion)
CAGR (2025-2035) 4.34%

Major Players

AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories (US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany), Evoke Pharma (US), Valent Pharmaceuticals (US)

Key Companies in the Americas Gastrointestinal Drugs Market market include

Report Scope

Report Attribute/Metric Details
Market Size 2023 11.2 (USD Billion)
Market Size 2024 12.34 (USD Billion)
Market Size 2032 16.7 (USD Billion)
Compound Annual Growth Rate (CAGR) 9.2 % (2024 - 2032)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2023
Market Forecast Period 2024 - 2032
Historical Data 2019 - 2023
  Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany). Evoke Pharma (US), Valent Pharmaceuticals(US)
  Key Market Opportunities Increasing cases of conditions like Crohn's disease, ulcerative colitis, and irritable bowel syndrome (IBS) drive demand for effective treatments.
  Key Market Drivers Increasing incidence of gastrointestinal diseases like GERD, IBS, and Crohn's disease.

Market Highlights

Author
Kinjoll Dey
Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Leave a Comment

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions